Ipsen strikes up to €700m deal for Swiss biotech firm
Paris-based listed global biopharmaceutical company Ipsen SA has acquired Swiss biotechnology firm Memo Therapeutics AG in a deal that could exceed €700m. This transaction will integrate a first-in-class asset into Ipsen’s clinical pipeline as it seeks to address high unmet medical needs in transplantation, and highlights a growing trend of major European pharmaceutical companies securing specialised platform technologies to drive…